Keywords:

Cardiol Croat

Cardiologia Croatica

Cardiol. Croat.

1848-543X 1848-5448

Croatian Cardiac Society

CC_11(10-11)_538

10.15836/ccar2016.538

Extended Abstract

RANK/RANKL/OPG gene polymorphisms and aortic valve stenosis – preliminary data

Zeljko

Martina

http://orcid.org/

¹Gošev

Igor

http://orcid.org/

http://orcid.org/0000-0001-7626-3534

Kozmar

Damir

http://orcid.org/0000-0002-1607-8705

Vujanić

Darko

¹Legčević

Zoran

http://orcid.org/0000-0001-6497-841x

http://orcid.org/0000-0003-1704-4416

Bešić

Dino

http://orcid.org/0000-0001-9688-8582

Paić

Frane

³ 1University Hospital Merkur, Zagreb, Croatia 2UMass Memorial Medical Center, Worcester, Massachusetts, United States of America 3University of Zagreb School of Medicine, Zagreb, Croatia

Address for correspondence: Martina Zeljko, Klinička bolnica Merkur, Zajčeva 19, HR-10000 Zagreb, Croatia. / Phone: +385-99-488-8568 / E-mail: martina.zeljko2@gmail.com

112016

11 10-11 538 538 0310201610102016

2016

Croatian Cardiac Society

Keywords: aortic stenosisgene polymorphismosteoprotegrineRANK/RANKL/OPG

Objective: Aortic valve stenosis (AS) is the most frequent heart valve disease among adults in the Western societies with ever increasing prevalence due to the rapidly ageing population. Currently there are no effective pharmacological therapies to prevent or slow the progression of AS and the surgical aortic valve replacement (AVR) or less invasive transcatheter aortic valve replacement (TAVR) procedure is still the only clinical therapy at hand for its successful treatment. Numerous research studies have shown association of genetic polimorphism with the prevalence of aortic valve stenosis. (1-3) Aims of this study are to assess the impact of RANK/RANKL/OPG gene polymorphisms on risk and severity of aortic stenosis. Herein we present the data for the rs3102735 osteoprotegrin (OPG/TNRSF11B) gene polymorphism.

Patients and Methods: The study included 92 AS patients and 131 healthy control subjects. The rs3102735 OPG gene polymorphism was identified using the quantitative real time polymerase chain reaction (qRT-PCR) and the TaqMan^® SNP Genotyping Assay (Life Technologies Corporation, Carlsbad, California, USA).

Results: The OPG rs3102735 (C/T transition, substitution) genotype and allele distribution in AS patients (CC=2.2%, CT=30.4% and TT=67.4%; C=17.4%, T=82. 6%) did not significantly (p>0.05) differ from those in control group (CC=0.8%, CT=22.9% and TT=76.3%; C=12.2%, T=87.8%). Also, no statistically significant difference was found between the AS patient and control subject group stratified by gender.

Conclusion: This patient-control study shows that rs3102735 osteoprotegrin (OPG/TNRSF11B) gene polymorphism is not genetic risk factors for AS..

Literature 1

Anger

Ekici

Daniel

Garlichs

. Gene polymorphisms leading to calcified and stenotic aortic valves. Herz. 2006;31(7):635–43. 10.1007/s00059-006-2881-z

17072776

Gaudreault

Ducharme

Lamontagne

Guauque-Olarte

Mathieu

Pibarot

Replication of genetic association studies in aortic stenosis in adults.

Am J Cardiol. 2011;108(9):1305–10. 10.1016/j.amjcard.2011.06.050

21855833

Makarović

Steiner

Mihaljević

Milas-Ahić

. Osteoprotegerin and Vascular Calcification: Clinical and Prognostic Relevance. Coll Antropol. 2015;39(2):461–8.26753467